SomnoMedSOMNF 49 FCF Margin % is 1.25% as of Dec. 2025. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, SomnoMed ranks better than 54.47% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SomnoMed's Free Cash Flow for the
six
months ended in Dec. 2025 was $0.50 Mil. SomnoMed's Revenue for the
six
months ended in Dec. 2025 was $40.34 Mil. Therefore, SomnoMed's FCF Margin % for the quarter that ended in Dec. 2025 was 1.25%.
The historical rank and industry rank for SomnoMed's FCF Margin % or its related term are showing as below:
SOMNF'
s FCF Margin % Range Over the Past 10 Years
Min: -18.3 Med: -10.16 Max: 5.24
Current: 1.57
During the past 13 years, the highest FCF Margin % of SomnoMed was 5.24%. The lowest was -18.30%. And the median was -10.16%.
SOMNF's FCF Margin % is ranked better than 54.47% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: -0.34
vs SOMNF: 1.57
SomnoMed FCF Margin % Related Terms
SomnoMed FCF Margin % Historical Data
* Premium members only.
The historical data trend for SomnoMed's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's FCF Margin % distribution charts can be found below:
* The bar in red indicates where SomnoMed's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (SOMNF) has a FCF Margin % of 1.25% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on SomnoMed and its competitors. According to the industry distribution chart, SomnoMed ranks #372 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 45.5%.
Is SomnoMed's FCF Margin % too high?
SomnoMed's current FCF Margin % is 1.25%. Based on the distribution chart, SomnoMed ranks #372 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #372 out of 817 companies for FCF Margin %. This puts SomnoMed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on SomnoMed and its competitors. SomnoMed's current FCF Margin % is 1.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $0.45 — trading 35.7% above its estimated fair value. The current FCF Margin % is 1.25%. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For SomnoMed (SOMNF), the current FCF Margin % is 1.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (SOMNF) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33.
GuruFocus considers SomnoMed to be Significantly Overvalued.
Key valuation signals for SOMNF:
FCF Margin %: 1.25%
GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score
Get the complete analysis for SOMNF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOMNF has been successfully added to your 
